Emgality™ (galcanezumab-gnlm)

Emgality is a CGRP blocker approved for the prevention of migraine and treatment of episodic cluster headache in adults. Emgality is manufactured by Eli Lilly and Company.

What is the main ingredient in Emgality?

The active ingredient in Emgality is galcanezumab, a monoclonal antibody.

How does Emgality work for migraine?

Emgality is a monoclonal antibody that targets CGRP. It attaches to the CGRP peptide ligand and blocks it from binding to the receptor. CGRP (calcitonin gene-related peptide) is a protein that has been discovered as a key component in some migraine attacks. CGRP is considered a neurotransmitter (a chemical messenger) and is present throughout the brain and body. Researchers have found that levels of CGRP are higher during a migraine attack, which led to the development of products to block the protein.

What are the possible side effects of Emgality?

Some patients in clinical trials experienced a hypersensitivity (allergic reaction) to Emgality, which can cause rash, itching, difficulty breathing, and swelling of the mouth, lips, tongue, or throat. The most common side effects experienced by patients taking Emgality in clinical trials were injection site reactions, such as soreness and redness.

These are not all the possible side effects of Emgality. Patients should talk to their doctor about what to expect with treatment with Emgality.

Things to know about Emgality

Emgality has not been studied in women who are pregnant or breastfeeding, and it is not known if Emgality may cause any risks to unborn or breastfeeding infants.

If a serious allergic reaction (hypersensitivity) occurs, patients should stop using Emgality. Treatment for the allergic reaction may be needed. Allergic reactions may occur days after the injection.

You should begin no medication or supplement without first checking with your health care provider and should let them know of any other prescriptions, OTCs, and herbals you are taking to ensure there are no interactions.

For more information, read the full prescribing information for Emgality.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

More on this topic

Written by: Emily Downward | Reviewed June 2021